NZ201822A

NZ201822A - Spiro-2h-indene(2,3')-3h-pyrazol(4",5":7',6')naptho(2,1-b)pyran-1,3-dione derivatives and pharmaceutical compositions

Info

Publication number: NZ201822A
Application number: NZ20182282A
Authority: NZ
Inventors: J L Herrmann; M R Bell
Original assignee: Sterling Drug Inc
Priority date: 1982-09-06
Filing date: 1982-09-06
Publication date: 1985-01-31

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number £01 8££ 201822 Pricriiy Date(s): • ■ q~<- ■' r- ■"Hcstion Filed: = vZltimiiWA h>Ms. ■ ■ " „ 31 JAN 1985 Publica'aon s-'&i®: .. • P.O. Jcurn>!, Uo\ !ol(o b • a ■ ■ • o a « a a ■ • $ F*?» % "POLYCYCLIC FUSED PYRAZOLE COMPOUNDS, USEFUL AS ANTIINFLAMMATORY AGENTS, AND PREPARATION THEREOF" f i/We, STERLING DRUG INC., a company incorporated in the State of Delaware, U.S.A., of 90 Park Avenue, New York, State of New York, United States of America # hereby declare the invention for which S/ we pray that a patent may be granted to Iffife/us, and the method by which it is to be performed, to be particularly described in and by the following statement:- - 1 - (followed by page la) 20182 -i2 The present invention relates to novel polycyclic fused pyrazole compounds, their use as anti-inflammatory agents, and a method of preparation thereof. Typical glucocorticoid activity is rarely found 5 in structures which do not possess an intact steroid nucleus. Such activity is found in naturally occurring steroids such as cortisone, hydrocortisone and aldosterone, as well as numerous synthetic modifications thereof, all containing the intact steroid nucleus. An example of a 10 synthetic cortical steroid having high activity is a fluorophenylpyrazole derivative reported by Fried et al., J. Am. Chem. Soc. 85, 236 (1963), having the structure The present invention relates to compounds 15 having the formula: 201822 -2- 10 where R is hydrogen or fluorine. A pharmaceutical composition for treating inflammation in mammals comprises an anti-inflammatorily effective amount of a compound of Formula I and a pharmaceutical^ acceptable carrier. One can reduce inflammation in a mammal by administering to said mammal an anti-inflammatorily effective amount of a compound of Formula I. One can prepare a compound of Formula I by reacting a compound of the formula: CH, II with 1/2,3-indantrione. The intermediates of Formula II are prepared from a known starting material, 5-ethenyl-4,4a,7,8- 201822 -3- tetrahydro-4a-methyl-2(3H)-naphthalenone U.S. Patent 4,157,349, in accordance with the following reactions: ch=ch2 0 HC0oCH_ —12-4 3 NaOCH^ ch=ch 2 NHNH 2 HOC 5 R The trienone starting material is reacted with methyl formate in the presence of sodium methoxide in an inert solvent such as tetrahydrofuran to afford 5-ethenyl-3-hydroxymethylene-4,4a,7,8-tetrahydro-4a-methyl-2(3H)- naphthalenone, and thle latter is then reacted with 10 phenylhydrazine or 4-fluorophenylhydrazine or an acid-addition salt thereof in the presence of acetic acid to give the compound of Formula II. The reaction of a compound of Formula II with 1,2,3-indantrione takes place by heating the reactants in 15 an inert solvent at a temperature between about 50° and 150°C. The compounds of Formula I exhibit an endocrinological profile characteristic of compounds possessing glucocorticoid properties and systemic and/or topical anti-inflammatory activity; cf. r.h. Silber. The 20 Biology of Anti-inflammatory Steroids, Annals of the New York Academy of Sciences, Vol. 82, Art. 4, pp. 821-828. When the compounds of Formula I are administered orally to rats they cause a significant depression in thymus weight, adrenal weight and body weight gain without 25 a change in food consumption. The compound of Formula I where R is F has also been found to possess oral glucocorticoid activity by the 201822 liver glycogen deposition test and anti-inflammatory activity by the a-tocopherol pouch test in rats. The test procedures used to determine the biological activities of the compounds of the invention 5 were carried out as follows: Endocrine Profile: Mature female rats with an average body weight of 2 02 g and a body weight range of 15 g or less were medicated orally with test compound for 2 weeks. The test compound was prepared as a solution 10 or suspension in 1% gum tragacanth or 0.75% methyl cellulose. On the day following the last medication, the rats were killed and the thymus and adrenal of each rat were removed, cleaned, and weighed. Body weights and food consumptions were also recorded. 15 Anti-inflammatory Activity (a-tocopherol pouch test): Male rats which weighed 120 g were selected for testing. A rapid subcutaneous injection of 25 mL of air was made between the scapulae of each rat. This resulted in the establishment of an airfilled pouch into which 0.5 20 mL of dl-a-tocopherol was injected. The test compound was administered in daily oral doses for 7 days beginning on the day of pouch formation. The compound to be tested was suspended in 1% gum tragacanth. Twenty-four hours after the last medication, the pouches were dissected free, 25 and the fluid volume was measured. The inhibition of liquid exudate is a measure of the anti-inflammatory activity. Glycogenic Activity: Mature male rats were bilaterally adrenalectomized 5 days prior to the test. 30 These rats were medicated orally with the test compound for 5 days. Seven hours after the last medication, the rats (which have been fasted overnight) were anesthetized with sodium pentobarbital and a portion of one lobe of the liver was removed and frozen on dry ice for subsequent 35 glycogen determination. The compounds of the invention can be formulated for topical application by solution or dispersion in a 2 0 1 B i -5- conventional pharmaceutically acceptable liquid, cream or ointment base. The effective ingredient is preferably present in a concentration of 0.01% to 5.0% by weight. The compounds of the invention can be formulated 5 for oral administration in tablet or capsule form with conventional excipients. The active ingredient is preferably present in an amount of 1 mg to 100 mg per unit dosage form. The following examples will further illustrate 10 the invention. Example 1 (a) 5-Ethenyl-3-hydroxymethylene-4,4a,7,8-tetrahydro-4a-methyl-2(3H)-naphthalenone. A solution of 50.0 g (0.265 mol) of 5-ethenyl-4, 15 4a,7,8-tetrahydro-4a-methyl-2(3H)-naphthalenone in 350 mL of tetrahydrofuran was cooled to -5°C. in an ice-methanol bath and stirred under nitrogen while 57.2 g (1.06 mol) of sodium methoxide was added. The resulting mixture was stirred for 3 0 min at -5°C. and then a solution of 114 mL 20 (1.85 mol) of methyl formate in 100 mL of tetrahydrofuran was added slowly. The mixture was stirred overnight at room temperature and then poured onto a mixture of ice-water (.1500 mL) and 6N hydrochloric acid (265 mL) . The product was extracted with ether and the combined extracts 25 were washed with water. The dried extract was dried over anhydrous magnesium sulfate and concentrated in vacuo to J afford an oil. This oil was triturated with hexane (4 x 250 mL) and the combined triturates were dried over magnesium sulfate and concentrated in vacuo to afford 30 55.37 g of a red oil, consisting essentially of the above-entitled compound as established by proton NMR (PMR) spectral data. (b) l-Ethenyl-6-(4-fluorophenyl)-3,4,9,9a-tetrahydro-9a-methyl-6H—naphtho[2,3-c]pyrazole (II; R = F). 35 4-Fluorophenylhydrazine hydrochloride (45.85 g, 0.28 2 mol) and sodium acetate (23.14 g, 0.282 mol) were added to a solution of 55.37 g (0.2 56 mol) of the product 201822 -6- obtained in part (a) above in 225 mL of glacial acetic acid. The mixture was stirred overnight at room temperature and then concentrated in vacuo to afford a semi-solid. This material was suspended in ether (1 L) and filtered 5 to remove sodium chloride. The ether filtrate was washed with water (4 x 250 mL), saturated sodium bicarbonate (until weakly basic) and saturated sodium chloride (100 mL). The extract was dried over anhydrous magnesium sulfate, decolorized with charcoal and concentrated in vacuo to 10 afford an oil. This oil was triturated with 1:2 ether- hexane C3 x 750 mL) to afford 69.58 g of a dark brown oil. An analytical sample was prepared by using high-performance liquid chromatography with 1:3 ether-hexane as solvent. The resulting yellow oil was triturated with pentane to 15 afford l-ethenyl-6-(4-fluorophenyl)-3,4, 9,9a-tetrahydro-9a-methyl-6H—naphtho[2,3-cJpyrazole (II; R = F) as a yellow solid, m.p. 70-72°C. with a consistent PMR spectrum. (c) 8'-C4-Fluorophenyl)-2',3',5',6',11',11a'-hexahydro-lla'-methylspiro-2H-indene[2,3']-3H-pyrazolo[4",5":7',6']-naphtho-20 [2,1-b]pyran-1,3-dione (I; R = F). A mixture of 15.3 g (0.05 mol) of II (R « F) (part b above) and 9.8 g (0.055 mol) of 1,2,3-indantrione monohydrate in 150 mL of xylene was refluxed for 2 hours. The cooled reaction mixture was filtered through silica 25 gel and concentrated in vacuo. The residue was crystallized from ethanol to afford 7.19 g of I ( R = F) as a tan solid, m.p. 210-211°C. The proton NMR spectrum (PMR) was consistent with the assigned structure. In the endocrine profile determination, Compound 30 I (R = F) at a dose level of 1 mg/kg caused a 61% reduction in thymus weight, 56% reduction in adrenal weight and 129% reduction in body weight gain as compared with the controls. In the a-tocopherol pouch test, Compound I (R ■ F) was active with ED^g = 10 mg/kg. In the glycogenic activity 35 test, Compound I (R = F) at a dose level of 9 mg/kg/day x 5 produced a liver glycogen deposition value of 21.8 +4.4 mg/g of tissue as compared to 2.2 + 0.04 mg/g for the </div>

Claims

20182Z -7- vehicle (1% gum tragacanth) alone. Example 2 (a) l-Ethenyl-6-phenyl-3,4,9,9a-tetrahydro-9a-methyl-6H-naphtho[2,3-c]pyrazole (II; R = H) was prepared according 5 to the procedure of Example 1/ part (b), while substituting a molar equivalent amount of phenylhydrazine hydrochloride for the 4-fluorophenylhydrazine hydrochloride of that example. The product was characterized by its PMR spectrum. (b) 2', 3', 5', 61,11',11a'-Hexahydro-lla'-methyl-8'-phenylspiro 10 2H-indene[2,3']-3H-pyrazolo[4",5":7',61]naphtho[2,1-b] pyran-1,3-dione (I; R = H). A mixture of 14.4 2 g (0.05 mol) of II (R B H) (part a above) and 9.88 g (0.06 mol) of 1,2,3-indantrione monohydrate in 150 mL xylene was refluxed for 2 hours, then 15 allowed to stand at room temperature for 55 hours and filtered to afford a green solid. This green solid was dissolved in methylene dichloride, filtered through silica gel and the solvent removed in vacuo. The residue was triturated with ether to afford 10.95 g of I (R « H) as a 20 yellow solid, m.p. 209-210°C. The PMR spectrum was consistent with the assigned structure. In the endocrine profile determination, Compound I (R = H) at a dose level of 5 mg/kg caused a 51% reduction in thymus weight, 38% reduction in adrenal weight, and 25 62% reduction in body weight gain as compared with the controls. Compound I (R = H) was inactive in the a-tocopherol pouch test at a dose level of 100 mg/kg. 201822 -8- What we claim is:

1. A compound of the Formula I (herein) where R is hydrogen or fluorine.

2. 8,-(4-Fluorophenyl)-2',3'-5',6',11',11a'-hexahydro-lla * -methylspiro-2H-indene [2,3'] -3H-pyrazolo [4", 5":7',6']naphtho[2,1-b]pyran-1,3-dione, according to claim 1.

3. 21, 31,5*,61,111,lla'-Hexahydro-lla'-methyl- 8'-phenylspiro-2H-indene[2,3']-3H-pyrazolo[4",5" :7',6 ' ] naptho[2,1-b]pyran-1,3-dione, according to claim 1.

4. A process for preparing a compound according to claim 1, which comprises reacting l-ethenyl-6-(4-R-phenyl) -3,4,9, 9a-tetrahydro-9a-methyl-6H-naphtho.[2, 3-c] pyrazole with 1,2,3-indantrione*

5. A process according to claim 4, wherein R is fluorine.

6. A pharmaceutical composition for treating inflammation in mammals which comprises an anti-inflammatorily effective amount of a compound according to any one of claims 1-3 and a pharmaceutical^ acceptable carrier.

7. A method of reducing inflammation in a ncn-human maximal which comprises administering to said mammal an anti-inflammatorily effective amount of a compound according to any one of claims 1-3.

8. A compound according to claim 1, or a composition according to claim 6, substantially as herein described with reference to any one of the Examples.

9. A process for preparing a compound according to claim 1, substantially as herein described with reference to any one of the Examples.

10. A compound when produced by the process according to any one of claims 4, 5, and 9. By k^y/chsfr authorised Agents., -20CTS984 1 A. J 4 SON GAS® 4-69-2—A \